Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells from bone marrow may replace traditional bone graft in spine surgery

NCT ID NCT02297256

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using a patient's own bone marrow stem cells (BMAC) mixed with donor bone works as well as the standard bone graft taken from the hip for spinal fusion surgery. Seventeen adults with degenerative disc disease were randomly assigned to one of the two methods. Researchers measured bone healing, pain, disability, and quality of life one year after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bone marrow aspirate concentrate (BMAC) with allograft
What this could lead to
If BMAC works as well as traditional bone graft, it could reduce the need for a separate surgical site to harvest bone, potentially lowering pain and recovery time.
What could go wrong
This is a very small, completed study with only 17 participants, so results may not apply to everyone. BMAC is still experimental for this use, and long-term benefits or risks are not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

Aug 2012

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be 18 years old or older * Scheduled for elective posterior spinal fusion of the thoracolumbar spine or lumbar spine with or without anterior interbody support * Failed at least 6 weeks of conservative care * ODI v2.1 score \> 30% * No contraindication to BMAC (as per manufacturer) * Signed consent form Exclusion Criteria: * Spondylolisthesis grade ≥ 3 * Pagets disease, osteomalacia, or any metabolic bone disease * Use of medications that interfere with bone healing (chronic steroids) * Patient unlikely to comply with post-op schedule with physician * Recent history of chemical dependency * Participation in other investigational device trial(s) within past 30 days * Active malignancy * Pregnancy or planning to become pregnant * Direct involvement in execution of this protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lumbar degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intervertebral disk degenerative disorder lumbar disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lumbar degenerative disc disease

Contacts and locations

Locations

  • Center for Musculoskeletal Care (CMC)

    New York, New York, 10016, United States

  • NY Spine Institute

    Westbury, New York, 11590, United States

  • NYU Hospital for Joint Diseases

    New York, New York, 10003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.